Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Breier

Showing results (31-40 of 110) with videos related to

Pageof 11
Sort By:
Clinical Neuropharmacology|October 22, 2005
Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instrumentsKelvin L Chou, Susan Messing, David Oakes, et al.
The New England Journal of Medicine|June 23, 2021
Clinical Trial of New Drug for Schizophrenia. ReplySteven M Paul, Alan Breier, Jeffrey A Lieberman, et al.
Early Intervention in Psychiatry|September 14, 2016
Characterization of white matter abnormalities in early-stage schizophreniaTom A Hummer, Michael M Francis, Jenifer L Vohs, et al.
Clinical Therapeutics|July 18, 2003
A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapyPadraig Wright, Karena Meehan, Martin Birkett, et al.
The New England Journal of Medicine|February 24, 2021
Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for SchizophreniaStephen K Brannan, Sharon Sawchak, Andrew C Miller, et al.
The Journal of Clinical Psychiatry|May 13, 2022
Antipsychotic Efficacy of KarXT (Xanomeline-Trospium): Post Hoc Analysis of Positive and Negative Syndrome Scale Categorical Response Rates, Time Course of Response, and Symptom Domains of Response in a Phase 2 StudyPeter J Weiden, Alan Breier, Sarah Kavanagh, et al.
Journal of Clinical Psychopharmacology|September 18, 2007
Neuroreceptor gene polymorphisms and olanzapine depressive symptom response in schizophreniaJohn P Houston, David H Adams, Sandra C Kirkwood, et al.
International Journal of Molecular Sciences|July 2, 2015
Metacognition in Early Phase Psychosis: Toward Understanding Neural SubstratesJenifer L Vohs, Tom A Hummer, Matthew G Yung, et al.
CNS Drugs|February 12, 2004
Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims databaseZhongyun Zhao, Madhav Namjoshi, Beth L Barber, et al.
Biological Psychiatry|September 21, 2002
Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's diseaseAlan Breier, Virginia K Sutton, Peter D Feldman, et al.
Pageof 11

Showing results (31-40 of 110) with videos related to

Sort By:
Pageof 11
Clinical Neuropharmacology|October 22, 2005
Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instrumentsKelvin L Chou, Susan Messing, David Oakes, et al.
The New England Journal of Medicine|June 23, 2021
Clinical Trial of New Drug for Schizophrenia. ReplySteven M Paul, Alan Breier, Jeffrey A Lieberman, et al.
Early Intervention in Psychiatry|September 14, 2016
Characterization of white matter abnormalities in early-stage schizophreniaTom A Hummer, Michael M Francis, Jenifer L Vohs, et al.
Clinical Therapeutics|July 18, 2003
A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapyPadraig Wright, Karena Meehan, Martin Birkett, et al.
The New England Journal of Medicine|February 24, 2021
Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for SchizophreniaStephen K Brannan, Sharon Sawchak, Andrew C Miller, et al.
The Journal of Clinical Psychiatry|May 13, 2022
Antipsychotic Efficacy of KarXT (Xanomeline-Trospium): Post Hoc Analysis of Positive and Negative Syndrome Scale Categorical Response Rates, Time Course of Response, and Symptom Domains of Response in a Phase 2 StudyPeter J Weiden, Alan Breier, Sarah Kavanagh, et al.
Journal of Clinical Psychopharmacology|September 18, 2007
Neuroreceptor gene polymorphisms and olanzapine depressive symptom response in schizophreniaJohn P Houston, David H Adams, Sandra C Kirkwood, et al.
International Journal of Molecular Sciences|July 2, 2015
Metacognition in Early Phase Psychosis: Toward Understanding Neural SubstratesJenifer L Vohs, Tom A Hummer, Matthew G Yung, et al.
CNS Drugs|February 12, 2004
Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims databaseZhongyun Zhao, Madhav Namjoshi, Beth L Barber, et al.
Biological Psychiatry|September 21, 2002
Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's diseaseAlan Breier, Virginia K Sutton, Peter D Feldman, et al.
Pageof 11